BNP Paribas Asset Management
KYMR icon

BNP Paribas Asset Management’s Kymera Therapeutics KYMR Stock Holding History

BNP Paribas Asset Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.07M Sell
61,657
-2,810
-4% -$241K 0.01% 803
2026
Q1 		$5.37M Sell
64,467
-308
-0.5% -$24.4K 0.01% 848
2025
Q4 		$5.04M Buy
64,775
+64,363
+15,622% +$4.35M 0.01% 838
2025
Q3 		$23K Buy
412
+69
+20% +$3.11K ﹤0.01% 1324
2025
Q2 		$15K Buy
+343
New +$11.8K ﹤0.01% 1620

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

BNP Paribas Asset Management's KYMR Position: Q2 2026 in Review

BNP Paribas Asset Management reduced its Kymera Therapeutics (KYMR) stake by 4.4% in Q2 2026, selling an estimated $241K and leaving 61,657 shares worth $7.07M. The position accounts for 0.01% of the portfolio, ranked #803.

BNP Paribas Asset Management first reported a position in KYMR in Q2 2025 and has held it in 5 quarters since. 276 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • BNP Paribas Asset Management held 61,657 shares of Kymera Therapeutics worth $7.07M as of Q2 2026.
  • BNP Paribas Asset Management sold 2,810 Kymera Therapeutics shares in Q2 2026, an estimated $241K.
  • Kymera Therapeutics made up 0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #803 holding.
  • BNP Paribas Asset Management first reported a position in Kymera Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 276 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.